abstract |
The invention belongs to the field of biomedicine, and in particular relates to a method for predicting the effect of a patient receiving TACE treatment. Specifically, the method includes the step of predicting the patient's response to TACE treatment by detecting the expression levels of any one or more of GAS2L3, LPCAT1, and NUDT6. Preferably, the patient is a liver cancer patient. |